The AFP-specific T cell response is common in patients with advanced-stage disease, which indicates the interaction between the protective role of the host T cell immune response to control the progression of HCC and the various mutations or antigenic drift from tumour cells to escape immune killing, immunoediting and immune surveillance [5, 42, 43]. This evidence concerns the gene AFP and neoplasm.